Adaptive Biotechnologies to Participate in the 43rd Annual Cowen Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the 43rd Annual Cowen Healthcare Conference in Boston, scheduled for March 6, 2023, at 12:50 p.m. Eastern Time. Management will engage in a fireside chat, with an accessible live and archived webcast available on the company’s website. The company focuses on leveraging the adaptive immune system's genetics to develop clinical products for diagnosing and treating diseases like cancer and autoimmune disorders. Their platform aims to transform disease management through precision and speed.

SEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43^rd Annual Cowen Healthcare Conference in Boston, Masssachusetts.

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Monday, March 6^th at 12:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE MEDIA
Erica Jones, Associate Director, Product Communications
206-279-2423
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies participate in the Cowen Healthcare Conference?

Adaptive Biotechnologies will participate in the Cowen Healthcare Conference on March 6, 2023, at 12:50 p.m. Eastern Time.

How can I access the Adaptive Biotechnologies conference presentation?

You can access the live and archived webcast of the Adaptive Biotechnologies conference presentation on their website in the 'Investors' section.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on utilizing the adaptive immune system's genetics to develop products for diagnosing and treating diseases such as cancer and autoimmune disorders.

What is the stock symbol for Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.

Where is the Cowen Healthcare Conference held?

The 43rd Annual Cowen Healthcare Conference is being held in Boston, Massachusetts.